Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract #2809: Combination treatment with the anti-IGF1R antibody MK-0646 and the mTOR inhibitor deforolimus leads to more effective PI3K pathway targeting and anti-tumor activity

Sriram Sathyanarayanan, Sharda Jha, Richard Klinghoffer, Youyuan Xu, Mark Bittinger, Jason Frazier, Alessandra Di Bacco, Michael Chastain, Astrid Kral, Nancy Kohl, Brian Haines, Katharine Yen, Shailaja Kasibhatla and Christopher Winter
Sriram Sathyanarayanan
Merck Research Laboratory, Boston, MA; Rosetta Inpharmatics LLC.,, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharda Jha
Merck Research Laboratory, Boston, MA; Rosetta Inpharmatics LLC.,, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Klinghoffer
Merck Research Laboratory, Boston, MA; Rosetta Inpharmatics LLC.,, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Youyuan Xu
Merck Research Laboratory, Boston, MA; Rosetta Inpharmatics LLC.,, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Bittinger
Merck Research Laboratory, Boston, MA; Rosetta Inpharmatics LLC.,, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason Frazier
Merck Research Laboratory, Boston, MA; Rosetta Inpharmatics LLC.,, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandra Di Bacco
Merck Research Laboratory, Boston, MA; Rosetta Inpharmatics LLC.,, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Chastain
Merck Research Laboratory, Boston, MA; Rosetta Inpharmatics LLC.,, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Astrid Kral
Merck Research Laboratory, Boston, MA; Rosetta Inpharmatics LLC.,, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy Kohl
Merck Research Laboratory, Boston, MA; Rosetta Inpharmatics LLC.,, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Haines
Merck Research Laboratory, Boston, MA; Rosetta Inpharmatics LLC.,, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katharine Yen
Merck Research Laboratory, Boston, MA; Rosetta Inpharmatics LLC.,, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shailaja Kasibhatla
Merck Research Laboratory, Boston, MA; Rosetta Inpharmatics LLC.,, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Winter
Merck Research Laboratory, Boston, MA; Rosetta Inpharmatics LLC.,, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

Components of the Insulin-like Growth Factor-1 (IGF1) signaling system are over-expressed by tumors, mediating proliferation and apoptosis resistance. Targeted therapies against IGF1R are currently being tested in the clinic. To support the clinical development of a humanized antibody targeting IGF1R, MK-0646, we have investigated molecular and cellular determinants for MK-0646 response. Inhibition of IGF1R in cells with high levels of the receptor significantly blocked the AKT signaling pathway. Despite inhibition of AKT signaling by MK-0646, only modest anti-proliferative activity was observed in most cell lines in vitro. To identify enhancers of MK-0646 anti-proliferative activity, a lentiviral-mediated RNAi screen targeting 480 distinct human kinases was performed in a colon cancer cell line, HT29. shRNAs targeting multiple components of the PI3K pathway significantly (P<0.02) enhanced anti-proliferative activity of MK-0646. These results suggest that combining MK-0646 with an inhibitor of a down-stream component in the PI3K pathway may significantly enhance anti-tumor activity. mTOR is a key downstream component of the PI3K signaling pathway which regulates protein translation and metabolism. Deforolimus (AP23573; MK-8669) is an analog of Rapamycin that acts as an allosteric inhibitor of mTOR in the context of the TORC1 complex. Deforolimus is being tested clinically for the treatment of multiple tumor types. While inhibition of TORC1 by deforolimus can induce tumor growth arrest, it abrogates a negative feedback loop mediated by IRS-1, resulting in activation of AKT. A recent clinical study suggested that activation of AKT via this feedback mechanism may be associated with a shorter time-to-progression in patients treated with rapamycin (Cloughesy et al PLoS Medicine, 2008). We find that combined inhibition of TORC1 & IGF1R eliminates IRS-1 mediated feedback activation of AKT and enhances PI3K pathway inhibition. The combination of MK-0646 and deforolimus significantly enhanced anti-proliferative activity of MK-0646. Importantly, this combination demonstrated enhanced anti-tumor activity in an erlotinib-resistant, KRAS-mutant lung cancer xenograft model (A549). These results suggest that multi-node targeting of PI3K signaling via co-treatment with MK-0646 and deforolimus is a rational approach for achieving enhanced anti-tumor activity.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 2809.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #2809: Combination treatment with the anti-IGF1R antibody MK-0646 and the mTOR inhibitor deforolimus leads to more effective PI3K pathway targeting and anti-tumor activity
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract #2809: Combination treatment with the anti-IGF1R antibody MK-0646 and the mTOR inhibitor deforolimus leads to more effective PI3K pathway targeting and anti-tumor activity
Sriram Sathyanarayanan, Sharda Jha, Richard Klinghoffer, Youyuan Xu, Mark Bittinger, Jason Frazier, Alessandra Di Bacco, Michael Chastain, Astrid Kral, Nancy Kohl, Brian Haines, Katharine Yen, Shailaja Kasibhatla and Christopher Winter
Cancer Res May 1 2009 (69) (9 Supplement) 2809;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #2809: Combination treatment with the anti-IGF1R antibody MK-0646 and the mTOR inhibitor deforolimus leads to more effective PI3K pathway targeting and anti-tumor activity
Sriram Sathyanarayanan, Sharda Jha, Richard Klinghoffer, Youyuan Xu, Mark Bittinger, Jason Frazier, Alessandra Di Bacco, Michael Chastain, Astrid Kral, Nancy Kohl, Brian Haines, Katharine Yen, Shailaja Kasibhatla and Christopher Winter
Cancer Res May 1 2009 (69) (9 Supplement) 2809;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

IGF-IR and PI3K Pathways -- Poster Presentations - Proffered Abstracts

  • Abstract #2826: CKAP4/p63 mediates antiproliferative factor (APF) inhibition of Akt/GSK3 signaling in T24 bladder carcinoma cells
  • Abstract #2816: Biologic effects of NVP-BEZ235, an orally available dual PI3K/mTOR inhibitor, in human breast, lung, colon, pancreas, and liver cancer cell lines in vitro.
  • Abstract #2821: Akt1 is involved in RhoC GTPase-mediated inflammatory breast cancer migration
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement